The stock of Avenue Therapeutics Inc (ATXI) has gone down by -36.41% for the week, with a -45.83% drop in the past month and a -44.89% drop in the past quarter. The volatility ratio for the week is 28.42%, and the volatility levels for the past 30 days are 13.37% for ATXI. The simple moving average for the past 20 days is -39.89% for ATXI’s stock, with a -80.41% simple moving average for the past 200 days.
Is It Worth Investing in Avenue Therapeutics Inc (NASDAQ: ATXI) Right Now?
Avenue Therapeutics Inc (NASDAQ: ATXI) has a price-to-earnings ratio of 1.27x that is above its average ratio. Additionally, the 36-month beta value for ATXI is -0.21. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ATXI is 0.52M and currently, short sellers hold a 0.01% ratio of that float. The average trading volume of ATXI on April 29, 2024 was 24.43K shares.
ATXI) stock’s latest price update
The stock of Avenue Therapeutics Inc (NASDAQ: ATXI) has decreased by -29.34 when compared to last closing price of 8.77.Despite this, the company has seen a loss of -36.41% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-11 that BAER-101 demonstrated full suppression of seizure activity in SynapCell’s GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans
ATXI Trading at -44.54% from the 50-Day Moving Average
After a stumble in the market that brought ATXI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.39% of loss for the given period.
Volatility was left at 13.37%, however, over the last 30 days, the volatility rate increased by 28.42%, as shares sank -43.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.53% lower at present.
During the last 5 trading sessions, ATXI fell by -36.41%, which changed the moving average for the period of 200-days by -92.68% in comparison to the 20-day moving average, which settled at $10.07. In addition, Avenue Therapeutics Inc saw -48.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATXI starting from Davidow Robert L, who sale 353,000 shares at the price of $0.14 back on Dec 11 ’23. After this action, Davidow Robert L now owns 22,000 shares of Avenue Therapeutics Inc, valued at $49,600 using the latest closing price.
Davidow Robert L, the 10% Owner of Avenue Therapeutics Inc, sale 264,000 shares at $0.14 during a trade that took place back on Dec 11 ’23, which means that Davidow Robert L is holding 681,000 shares at $36,960 based on the most recent closing price.
Stock Fundamentals for ATXI
The total capital return value is set at -22.23. Equity return is now at value -378.24, with -238.69 for asset returns.
Currently, EBITDA for the company is -14.54 million with net debt to EBITDA at 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.55.
Conclusion
In conclusion, Avenue Therapeutics Inc (ATXI) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
